New to Ophthalmology Job Center?
Registered users may Sign In.
Get maximum exposure and increase the rate of qualified responses with our Featured Job and Talent Blast Add-Ons.
Convenient. Automated. Hassle-Free.
If you have more than 10 jobs to post, or post multiple jobs frequently, please consider our bulk posting option.
Aerpio Therapeutics Initiates Phase 2 Study of Tie2 Activator AKB-9778 for the Treatment of Diabetic Macular Edema
CINCINNATI--(BUSINESS WIRE)-- Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis®) for the treatment of diabetic macular edema (DME). AKB-9778 is a ...
For Customer Service please contact 1-888-491-8833 Ext. 2239 (Extension Required) or firstname.lastname@example.org